Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023)
Ani Pharmaceuticals (ANIP) reported Restructuring Costs of $2000.0 for Q2 2023, down 99.92% on a YoY basis from $2.6 million in Q2 2022, and down 99.82% sequentially from $1.1 million in Q1 2023.
Ani Pharmaceuticals (ANIP) Restructuring Costs (2022 - 2023) Analysis & Trends
Ani Pharmaceuticals (ANIP) has 2 years of Restructuring Costs data on file, last reported at $2000.0 in Q2 2023.
- For the quarter ending Q2 2023, Restructuring Costs fell 99.92% year-over-year to $2000.0; the trailing twelve-month figure through Mar 2024 stood at $2000.0 (down 99.97% YoY), and the FY2023 full-year result was $1.1 million, down 80.07% from the prior year.
- Restructuring Costs fell to $2000.0 in Q2 2023, from $1.1 million in the prior quarter.
- In the past five years, Restructuring Costs ranged from a high of $2.6 million in Q2 2022 to a low of $2000.0 in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn |
| 10 | Ani Pharmaceuticals | 1.64 Bn | 1.33 Bn | 143.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 2,000.00 |
| Mar 31, 2023 | 1.13 Mn |
| Dec 31, 2022 | 1.20 Mn |
| Sep 30, 2022 | 1.54 Mn |
| Jun 30, 2022 | 2.57 Mn |